This complex role is further complicated by the existence of VEGF splice variants that can promote (pro-angiogenic) or inhibit (anti-angiogenic) angiogenesis, thereby influencing the tumor microenvironment and response to therapy. This evidence concerns the gene VEGFA and neoplasm.